FINNENCE ▪ THE WIRE FILE
THE WIRE · № 84054
News▼ Bearish
Azitra, Inc. Announces Reverse Stock Split
KINDNews
DIRECTION▼ Bearish
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A reverse split signals a depressed share price and is often cosmetic rather than fundamental.
Reverse split is a distress signal, not a fix
CATALYST TO WATCH
Post-split trading and listing compliance
MAIN RISK
Split may precede further dilution
FULL DISPATCH
Common Stock Will Begin Trading on a Split-Adjusted Basis on October 26, 2026 BRANFORD, Conn., Oct. 16, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Antihypertensive Drugs Market to Reach USD 30.92 Billion by 20352026-10-16 12:24 UTC
Antihypertensive Drugs Market to Reach USD 30.92 Billion by 20352026-10-16 12:24 UTC
→CORRELATIONshares Healthcare
Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia2026-10-16 12:30 UTC
Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia2026-10-16 12:30 UTC
→CORRELATIONshares Healthcare
Actinium Pharmaceuticals Announces Oral and Poster Presentations at EANM 2026 Highlighting Broad Antitumor Activity of ATNM-400 Across Lung, Colorectal and Ovarian Cancer Models2026-10-16 12:30 UTC
Actinium Pharmaceuticals Announces Oral and Poster Presentations at EANM 2026 Highlighting Broad Antitumor Activity of ATNM-400 Across Lung, Colorectal and Ovarian Cancer Models2026-10-16 12:30 UTC
→CORRELATIONshares Healthcare
Cyrano Therapeutics Announces Presentation of Positive Phase 2 FLAVOR Data Demonstrating Statistically Significant Improvement in Smell Function with CYR-064 in Patients with Post-Viral Smell Loss2026-10-16 12:30 UTC
Cyrano Therapeutics Announces Presentation of Positive Phase 2 FLAVOR Data Demonstrating Statistically Significant Improvement in Smell Function with CYR-064 in Patients with Post-Viral Smell Loss2026-10-16 12:30 UTC
→CORRELATIONshares Healthcare
CTY IPO News - City Therapeutics prices upsized IPO at $18, the midpoint of the range2026-10-16 12:47 UTC
CTY IPO News - City Therapeutics prices upsized IPO at $18, the midpoint of the range2026-10-16 12:47 UTC
→CORRELATIONshares Healthcare
Health Care and Crude Led the Week While Tech Lost Its Grip2026-10-16 13:10 UTC
Health Care and Crude Led the Week While Tech Lost Its Grip2026-10-16 13:10 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.